Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.
Most pharmaceuticals sold today have their origin in a biochemistry laboratory. Drug discovery has traditionally started with a biochemical pathway implicated in a pathophysiological process. An ...
The Brighterside of News on MSN
High-fat diets may lead to liver cells becoming cancerous
Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...
Nandita Vijayasimha, Bengaluru Friday, January 2, 2026, 08:00 Hrs [IST] ...
StockStory.org on MSN
1 profitable stock to own for decades and 2 facing challenges
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...
Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...
A big-data analysis shows that online content represents men as older than women in the same occupations and social roles, and that AI reproduces these warped presentations. Learning and embodiment ...
Copyright 2020 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals Stocks: Real-time U.S. stock quotes reflect trades reported through ...
Global investors will actively seek opportunities this year in undervalued pockets of financial markets as growing concerns over an AI bubble push traders to look beyond highly valued technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback